Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can a wearable glucose sensor be trusted in the ICU? new study aims to find out

NCT ID NCT07611721

Knowledge-focused Sponsor: Institute for Clinical and Experimental Medicine Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study is checking how accurate the Dexcom G7 continuous glucose monitor is for patients in the intensive care unit after major abdominal surgery or organ transplant. Researchers will place two sensors on each patient—one that is calibrated and used to guide insulin dosing, and one that is not calibrated and kept hidden. By comparing the readings from both sensors to standard blood glucose measurements, they hope to determine whether the device can reliably detect dangerous highs and lows in blood sugar in critically ill patients.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dexcom G7 continuous glucose monitor (device)
What this could lead to
If successful, this could show that the Dexcom G7 is reliable enough for routine use in intensive care, potentially improving glucose management for critically ill patients.
What could go wrong
This is a small, early-stage accuracy study (62 participants) in a specific ICU setting, so results may not apply to all patients or general hospital wards. The device may still have errors in detecting very low or high blood sugar.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 62 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jan 2026

Expected to finish

Apr 2027

An estimate. End dates often move.

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age 18 years or over * Intensive care unit admission * Requiring blood glucose monitoring for insulin therapy Exclusion Criteria: * High-dose ascorbic acid or acetaminophen \> 4g/day * Physical or mental health condition precluding continuous wear of the continuous glucose monitor, as judged by the physician

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CGM are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

congenital primary megaureter diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CGM Diabetes (insulin-requiring, type 1 or type 2) Intensive care (ICU) Liver transplant surgery Major abdominal surgeries Solid organ transplantation

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Institute of Clinical and Experimental Medice

    RECRUITING

    Prague, Czechia

More trials for these conditions

Other studies related to the condition(s) this trial covers.